Refactor BioSciences is a drug discovery company dedicated to repositioning existing therapeutics for rare and orphan diseases.


The company's current portfolio consists of a family of compounds that focus on anti-inflammation therapeutics. Refactor has identified three orphan indications and two general indications for this compound family.

To identify opportunities for our pipeline, Refactor BioScience has constructed a target-disease knowledge base for identifying repositioning opportunities for real-world testing.

Refactor leverages machine learning techniques, such as natural language processing and machine learning classification techniques for obtaining and enriching data sets. We leverage graph based analysis methods to identify new compound / disease combinations for our early stage pipeline.